This sequencing research panel assesses 316 genes known to harbor variants associated with vision impairment.
The research panel assesses 316 vision impairment-related genes. In addition to targeting all coding regions, an additional 50 non-coding disease-causing loci are targeted, as well as special coverage of two repeat expansion regions, in genes CNBP and ATXN7.
AmpliSeq for Illumina Community Panels are made-to-order. We provide the designs for your convenience; however, they do not have associated performance metrics. For predesigned and tested content, view AmpliSeq for Illumina Ready-to-Use Panels.
AmpliSeq for Illumina Community Panels contain content selected and designed with input from leading disease researchers. You can order this community panel as is, or customize the panel to meet your needs, using DesignStudio software to add or remove genes and amplicons.
| Input quantity | 1–100 ng; recommended 10 ng per pool |
|---|---|
| Method | Amplicon sequencing |
| Nucleic acid type | DNA |
| Number of amplicons | 5241 total. 2 pools. (Pool 1: 2627 amplicons. Pool 2: 2614 amplicons). |
| Species category | Human |
| Technology | Sequencing |
In addition to the community panel, you will also need an AmpliSeq Library PLUS kit and index adapters.
AmpliSeq™ Ophthalmic Research Panel for Illumina®
20020497
Sufficient for 3000 samples with > 4999 amplicons. Purchase Library PLUS and index adapters separately.
List Price:
Discounts:
Showing of
Product
Qty
Unit Price
Product
Catalog ID
Quantity
Unit price
Advanced chemistry, optics, and informatics combine to deliver exceptional speed and data quality, outstanding throughput and scalability.
Optimized reagent kit that provides increased cluster density and read length, improving sequencing quality scores compared to earlier versions.
Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.
A fast, integrated workflow for preparing libraries for use in a wide range of sequencing applications.
Reach out for information about our products and services, or get answers to questions about our technology.
Your email address is never shared with third parties.
